I have a buy order in for 10,000 shares at .60.
Post# of 36537
Although, I’m concerned about some of the acquisition strategy. Such as Hema not being worth anywhere near what GNBT paid, GNBT not recognizing the OBVIOUS legal problems concerning Veneto/Medoc, and too much in royalities on sales plus shares and cash to Bird of MediSource and Pantheon.
Ae37 Ii-key hybrid all the way.